... earned:
This session: ...
Per second: ...
← Back to list
Kiran Mazumdar-Shaw
#1183

Kiran Mazumdar-Shaw

Source of wealth: Biopharmaceuticals

Net Worth

...

Earnings per second

...

Modules

Biography

Kiran Mazumdar-Shaw, one of India's richest self-made women, founded biopharmaceutical firm Biocon, in 1978. The firm has successfully forayed into the lucrative U.S. market, and it also has one of Asia's largest insulin factories in Malaysia's Johor region.

In December 2025, Biocon announced that it is buying the rest of privately held subsidiary Biocon Biologics to consolidate its biosimilars and generics drug businesses. The deal values Biocon Biologics at $5.5 billion, it said.

Biocon Biologics acquired the biosimilars business of U.S. drugmaker Viatris in 2022 for $3.3 billion.

In 2022, the Central Bureau of Investigation arrested a Biocon Biologics executive and four others in an alleged bribery case. The company denied any wrongdoing.

Biocon-backed cancer therapy company Bicara Therapeutics raised $362 million in an IPO on the Nasdaq in September 2024.

Financial Assets

Exchange
NASDAQ
Ticker
BCAX-US
Company
Bicara Therapeutics
Exchange
BSE INDIA
Ticker
532523-IN
Company
Biocon
Exchange
BSE INDIA
Ticker
539551-IN
Company
Narayana Hrudayalaya

The Great Lie of Mega-Fortunes: The Case of Kiran Mazumdar-Shaw

Billionaires are often presented under the romantic myth of the 'self-made person': a narrative designed to justify opulence as the natural reward for hard work, effort, or ingenuity. However, when confronting such extreme volumes of wealth with macroeconomic reality, the meritocracy narrative completely breaks down. No individual can legitimately generate through personal effort a fortune equivalent to millions of times the average working-class salary. Capital at the top does not grow because of exceptional talent; it expands through an implacable dynamic where accumulated money works exponentially faster than people, devouring the wealth generated by productive labor.

The immense fortune of Kiran Mazumdar-Shaw, linked to Healthcare and 'Biopharmaceuticals', has not been built in a free-market vacuum, but through rent-seeking, the use of exclusive elite influence, the consolidation of monopoly positions, or inherited wealth. Far from taking real private risks, billionaire empires structurally depend on state support through direct subsidies, infrastructure use, exploitation of R&D, public contracts, and offshore tax engineering. While this wealth is equivalent to the physical weight of 26 tons of pure gold, the rest of the planet suffers from an artificial scarcity of basic resources. The fact that this wealth is enough to fully fund the public health system of DR Congo, a country with more than 105800000 million inhabitants for 1.6 years, proves that unlimited accumulation is not an entrepreneurial achievement, but the hijacking of democratic sovereignty.

Share

𝕏 Share on X 💬 Send via WhatsApp ✈️ Send via Telegram f Share on Facebook